Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead to Acquire Genentech Facility

by Ann M. Thayer
August 15, 2011 | A version of this story appeared in Volume 89, Issue 33

Gilead Sciences is buying a Genentech process research and small-scale biologics manufacturing facility in Oceanside, Calif., where it will produce monoclonal antibodies for clinical studies. Among these is GS 6624, which Gilead acquired in January from Arresto Biosciences and is developing to treat certain cancers and fibrotic diseases. Gilead will offer jobs to about 55 Genentech manufacturing and process development employees. Genentech still owns and operates a commercial manufacturing facility in Oceanside.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.